Two days ago, hedge-manager Wililam Ackman gave up in his fight with J.C. Penney (JCP) and resigned from the board. Today, details were released of an agreement between Ackman and the company to dispose of his approximately 18% position in the company.
APThe Wall Street Journal’s MoneyBeat has the details:
Pershing will be allowed to make up to four large sales, and each time must sell more than 5 million shares, and must request permission to do so from the company, who can delay the offering in certain instances. Pershing can make up to two requests per year but not more than four in total…
According to the agreement,�filed with the SEC�on Friday morning, the two sides entered into a pact on Tuesday, the day Mr. Ackman�� resignation from the board was announced.
Citigroup’s Deborah Weinswig considers the impact on J.C. Penney’s shares:
Top 5 Gas Utility Stocks To Invest In Right Now: Duke Realty Corporation (DRE)
Duke Realty Corporation operates as a real estate investment trust (REIT) in the United States. It offers leasing, property and asset management, development, construction, build-to-suit, and other tenant-related services. As of December 31, 2006, Duke Realty owned approximately 721 industrial, office, and retail properties comprising 113.8 million rentable square feet, as well as owned 6,400 acres of unencumbered land for development. The company has elected to be taxed as REIT under the Internal Revenue Code. As a REIT, it would not be subject to federal income tax purposes, provided that it distributes at least 90% of its REIT taxable income to its shareholders. The company was founded in 1972 and is headquartered in Indianapolis, Indiana with regional offices in Alexandria, Virginia; Atlanta, Georgia; Cincinnati, Columbus, and Cleveland, Ohio; Chicago, Illinois; Dallas and Houston, Texas; Minneapolis, Minnesota; Nashville, Tennessee; Orlando, Florida; Phoenix, Arizona; Raleigh, North Carolina; St. Louis, Missouri; and Tampa and Weston, Florida.
Advisors' Opinion:- [By Brad Thomas]
Other REITs mentioned: (O), (NNN), (STAG), (DCT), (EGP), (PDM), (DRE), (LRY)
Source: Chambers Street: More Liquidity Magic On The Way In REIT-DomDisclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. (More...)
Top 5 Gas Utility Stocks To Invest In Right Now: Parker Drilling Company(PKD)
Parker Drilling Company, together with its subsidiaries, provides contract drilling and drilling-related services in the United States, Latin America, Africa and the Middle East (AME), the Asia Pacific, and Commonwealth of Independent States (CIS). As of December 31, 2010, its fleet consisted of 11 rigs in the CIS/AME region; 10 rigs in the Americas region, including 7 land rigs and 1 barge rig in Mexico, and 2 land rigs in Colombia; 5 land rigs in the Asia Pacific region, including 2 rigs in Indonesia, 1 rig in Papua New Guinea, and 2 rigs in New Zealand; 13 barge drilling rigs in the inland shallow waters of the U.S. Gulf of Mexico; and 1 unassigned land rig held in New Iberia, Louisiana. The company also offers premium rental tools, including drill pipe, drill collars, tubing, high- and low-pressure blowout preventers, choke manifolds, junk and cement mills, and casing scrapers for land and offshore oil and gas drilling and workover activities. In addition, it provides non-capital intensive services, such as front end engineering and design; engineering, procurement, construction, and installation; operations and maintenance; and other project management services, which include labor, maintenance, and logistics for operators who own their own drilling rigs. The company serves independent and national oil and gas companies, and integrated service providers. Parker Drilling Company was founded in 1934 and is headquartered in Houston, Texas.
Advisors' Opinion:- [By Rich Smith]
Houston-based Parker Drilling Co. (NYSE: PKD ) has a new CFO.
On Thursday, Parker announced that it has hired away offshore driller Ensco plc's vice president and treasurer, Christopher T. Weber, to become its own senior VP and Chief Financial Officer. Weber will take office on May 20.
- [By Garrett Cook]
In trading on Wednesday, energy shares were relative leaders, up on the day by about 0.59 percent. Top gainers in the sector included Parker Drilling Co (NYSE: PKD), Alpha Natural Resources (NYSE: ANR), and Resolute Energy (NYSE: REN).
Best Life Sciences Companies To Invest In 2015: News Corporation(NWSA)
News Corporation operates as a diversified media company worldwide. Its Cable Network Programming segment produces and licenses news, business news, sports, general entertainment, and movie programming for distribution through cable television systems and direct broadcast satellite operators primarily in the United States, Latin America, Europe, and Asia. The company?s Filmed Entertainment segment produces and acquires live-action and animated motion pictures for distribution and licensing in entertainment media, as well as produces and licenses television programming worldwide. Its Television segment operates 27 broadcast television stations in the United States. The company?s Direct Broadcast Satellite Television segment distributes programming services via satellite and broadband directly to subscribers in Italy. Its Publishing segment provides newspapers and information services, such as publishing national newspapers in the United Kingdom, approximately 146 newspapers in Australia, and a metropolitan and a national newspaper in the United States; book publishing services, including the publishing of English language books worldwide; and integrated marketing services comprising the publishing of free-standing inserts, which are marketing booklets containing coupons, rebates, and other consumer offers, as well as provides in-store marketing products and services, primarily to consumer packaged goods manufacturers in the United States and Canada. The company also sells advertising, sponsorships, and subscription services on the company?s various digital media properties and outdoor advertising space on various media primarily in Russia and eastern Europe; and provides data systems and professional services that enable teachers to use data to assess student progress and deliver individualized instructions. News Corporation was founded in 1922 and is headquartered in New York, New York.
Advisors' Opinion:- [By Gary Bourgeault]
Storyful acquired by News Corp.
It was an excellent decision by News Corp. (NASDAQ: NWSA ) to acquire Storyful for $25 million. The company now has the resources to scale out much quicker in what will become a crowded market. - [By Lee Jackson]
News Corp. (NASDAQ: NWSA) boasts a cable-leading news operation and a host of additional entertainment properties. The consensus target for the stock is $17.30.
- [By Sue Chang]
On the earnings front, News Corp (NWSA) �is expected to report fiscal first-quarter earnings of 5 cents a share, according to a consensus survey by FactSet. In June, the media company separated its entertainment arm to operate as 21st Century Fox Inc. (FOXA) �while the publishing business retained the News Corp name. News Corp owns The Wall Street Journal and MarketWatch, the publisher of this report.
- [By WALLSTCHEATSHEET]
News Corp. provides a wide range of media and information services to consumers and companies interested in the latest and greatest around the world. The stock has been on a strong run in recent years but is now seeing a slight pullback that may take some time. Over the last four quarters, earnings and revenue figures have been improving, however, investors have had mixed feelings about their reports. Relative to its peers and sector, News Corp. has been a year-to-date performance leader. Look for News Corp. to continue to OUTPERFORM.
Top 5 Gas Utility Stocks To Invest In Right Now: Akamai Technologies Inc.(AKAM)
Akamai Technologies, Inc. provides content delivery and cloud infrastructure services for accelerating and improving applications over the Internet in the United States and internationally. The company offers application and cloud performance solutions to enhance the operation of the applications used by enterprises to connect with their employees, suppliers, and customers. Its solutions include Web Application Accelerator, which enables enterprises to run various applications; and IP Application Accelerator that is designed to optimize the performance, availability, and real-time sensitivity associated with IP-enabled applications delivered over Internet-related protocols. The company also provides video and software solutions that are designed to enable enterprises to execute their large file management and distribution strategies, which include media delivery solution to entertainment industry; and electronic software delivery solution that handles the distribution of s oftware for its customers. In addition, it offers Website optimization services for accelerating business-to-consumer Websites that integrate collaborative content and applications into their online architecture; security and protection solutions that address the Internet security requirements; and network operator solutions, which provide custom solutions to commercial and government customers. Further, the company provides mobile content adaptation solution; and advertising decision solutions that enable advertisers, agencies, publishers, and networks to buy and sell advertising, as well as network data feeds, Website analytics, and business performance management services. It markets and sells its services and solutions through direct sales and services organization; and through active channel partners. Akamai Technologies, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.
Advisors' Opinion:- [By John Kell]
Akamai Technologies Inc.(AKAM) said fourth-quarter earnings rose 18%, helped by a jump in revenue. Shares surged 16% premarket to $55.20.
AOL Inc.(AOL) said its fourth-quarter revenue climbed a bigger-than-expected 13%, driven primarily by stronger global advertising revenue. Shares climbed 6.1% to $50.45 premarket.
- [By jaggom]
Akamai (AKAM) and Limelight (LLNW) are two completely different prospects that investors can consider in the content delivery services space. Both have been performing differently. Let's take a look at which one suits investors' portfolios the best.
Top 5 Gas Utility Stocks To Invest In Right Now: Merrimack Pharmaceuticals Inc (MACK)
Merrimack Pharmaceuticals, Inc., incorporated in 1993, is a biopharmaceutical company discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. The Company�� product candidates include MM-398, MM-121, MM-111, MM-302 and MM-151. As of June 31, 2011, the Company owned approximately 74% interest of Silver Creek.
The Company�� Network biology is an interdisciplinary approach to drug discovery and development that enables the Company to build functional and predictive computational models of biological systems based on quantitative, kinetic, multiplexed biological data. The Company provides its scientists with insights into how the complex molecular interactions that occur within cell signaling pathways, or networks, regulate cell decisions and how dysfunction within these networks leads to disease. The Company applies network biology throughout the research and development process, including for target identification, lead compound design and optimization, diagnostic discovery, in vitro and in vivo predictive development and the design of clinical trial protocols.
MM-398
MM-398 is a stable nanotherapeutic encapsulation, or enclosed sphere carrying an active drug, of the marketed chemotherapy drug irinotecan. MM-398 achieved its primary efficacy endpoints in Phase 2 clinical trials in pancreatic and gastric cancer. In an open label, single arm Phase 2 clinical trial of MM-398 as a monotherapy in 40 metastatic pancreatic cancer patients who had previously failed treatment with gemcitabine, patients treated with MM-398 achieved median overall survival of 22.4 weeks. Additionally, 20% of the patients in this Phase 2 trial survived for more than one year, and the Company observed a disease control rate, meaning patients exhibited stable disease or partial or complete response to treatment, of 47.5% at six weeks.
The Company focuses on initiati! ng a Phase 3 clinical trial of MM-398 for the treatment of patients with metastatic pancreatic cancer who have previously failed treatment with gemcitabine. The trial is expected to enroll approximately 250 patients and is designed to compare the efficacy of MM-398 as a monotherapy against the combination of the chemotherapy drugs fluorouracil, or 5-FU, and leucovorin. There are multiple ongoing Phase 1 and Phase 2 clinical trials of MM-398. In July 2011, the United States Food and Drug Administration (FDA) granted MM-398 orphan drug designation for the treatment of pancreatic cancer.
MM-121
MM-121 is a fully human monoclonal antibody that targets ErbB3, a cell surface receptor, or protein attached to the cell membrane that mediates communication inside and outside the cell, that the Company�� network biology approach identified as a target in a range of cancers. A monoclonal antibody is a type of protein normally produced by cells of the immune system that binds to just one epitope, or chemical structure, on a protein or other structure. MM-121 is designed to inhibit cancer growth directly, restore sensitivity to drugs to which a tumor has become resistant and delay the development of resistance of a tumor to other agents. In collaboration with Sanofi, the Company focuses on testing MM-121 in combination with both chemotherapies and other targeted agents across a range of spectrum of solid tumors, including lung, breast and ovarian cancers. The Company partnered MM-121 with Sanofi after it initiated Phase 1 clinical development of the product candidate.
MM-111
MM-111 is a bispecific antibody designed to target cancer cells that are characterized by overexpression of the ErbB2 cell surface receptor, also referred to as HER2. A bispecific antibody is a type of antibody that is able to bind simultaneously to two distinct proteins or epitopes. The Company�� network biology approach identified that ligand-induced signaling through the complex of ErbB2 ! (HER2) an! d ErbB3 is a promoter of tumor growth and survival than previously appreciated.
MM-302
MM-302 is a nanotherapeutic encapsulation of doxorubicin with attached antibodies that are designed to target MM-302 to cells that over express the ErbB2 (HER2) receptor. The Company is conducting a Phase 1 clinical trial of MM-302 in patients with advanced ErbB2 (HER2) positive breast cancer.
MM-151
MM-151 is an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor (EGFR). EGFR is also known as ErbB1. An oligoclonal therapeutic is a mixture of two or more distinct monoclonal antibodies. The Company has designed MM-151 to block signal amplification that occurs within the ErbB cell signaling network. The Company has submitted an investigational new drug application (IND), to the FDA for MM-151 in July 2011.
Advisors' Opinion:- [By Keith Speights]
Not so merry
Merrimack Pharmaceuticals (NASDAQ: MACK ) shareholders have had reason to party since early May, with the stock surging more than 60%. The merriment came to a stop this week, though, as shares tanked by 27%. - [By John Udovich]
One way or the other, Merrimack Pharmaceuticals Inc (NASDAQ: MACK), Covidien plc (NYSE: COV), NeoGenomics, Inc (NASDAQ: NEO) and�CollabRx Inc (NASDAQ: CLRX) are targeting Barrett's Esophagus�or�esophageal cancer�(the former often leads to the latter) ��a form of cancer that may not be on the top of your list of cancers but is nevertheless on the rise. Approximately 3 million Americans suffer from Barrett's Esophagus, �a condition that�develops as a result of chronic injury from gastroesophageal reflux disease (GERD) where the�normal esophageal lining is replaced with abnormal cells (known as Barrett�� tissue), putting patients at greater risk of developing cancer of the esophagus. And although less than 1% of these patients develop cancer each year, esophageal carcinoma is frequently not detected until later stages, at which point therapy options are limited, extremely invasive, and often ineffective.�This means that�early detection is important�along with�regular surveillance is recommended.�
- [By Eric Volkman]
Merrimack Pharmaceuticals (NASDAQ: MACK ) is gearing up for a double dose of fund-raising. The company announced that it will concurrently float both a common stock and a convertible notes issue in a public offering. In the former, Merrimack will offer $50 million worth of shares, while the latter will take the form of $75 million in senior notes maturing in 2020. Additionally, the company expects that it will grant its underwriters a 30-day purchase option for up to an additional $7.5 million worth of common shares and $11.25 million of the convertible notes.
- [By Roberto Pedone]
One under-$10 biopharmaceuticals player that's just starting to trigger a breakout trade is Merrimack Pharmaceuticals (MACK), which focuses on discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. This stock has been hit hard by the bears so far in 2013, with shares off by 38%.
If you take a look at the chart for Merrimack Pharmaceuticals, you'll notice that this stock has been downtrending badly for the last two months, with shares plunging from its high of 7.09 to its recent low of $3.26 a share. During that move, shares of MACK have been consistently making lower highs and lower lows, which is bearish technical price action. That said, shares of MACK have just formed a double bottom chart pattern at $3.26 to $3.32 a share and it's now starting to break out above some near-term overhead resistance at $3.64 a share. This move could be signaling a trend change for MACK as the stock starts to move higher off oversold conditions.
Traders should now look for long-biased trades in MACK if it manages to break out above some near-term overhead resistance at $3.64 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 1.87 million shares. If that breakout triggers soon, then MACK will set up to re-test or possibly take out its next major overhead resistance level at its 50-day moving average of $4.75 a share. Any high-volume move above that level and above more resistance at $5.06 will then give MACK a chance to tag its 200-day moving average at $5.71 a share.
Traders can look to buy MACK off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $3.32 or at $3.26 a share. One can also buy MACK off strength once it clears $3.64 a share with volume and then simply use a stop tha
No comments:
Post a Comment